Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 5/20 | 0.37 |
| ▸ | TAB1 | Q15750 | 5/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.37 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14917666 | 0.86 | KDM2B (0.41) | KDM2BCPB1 | |
| SCHEMBL2818380 | 0.81 | FAAH (0.42) | KDM2BCPB1 | |
| SCHEMBL2822355 | 0.79 | KDM2B (0.48) | KDM2BMETCPB1 | |
| SCHEMBL18711426 | 0.78 | SPR (0.46) | BACE1KDM2BLRRK2 | |
| SCHEMBL1268836 | 0.78 | — | — | |
| SCHEMBL25392146 | 0.77 | BACE1 (0.34) | BACE1KDM2BMETMAP3K7TAB1 | |
| SCHEMBL25392153 | 0.77 | BACE1 (0.34) | BACE1KDM2BMETMAP3K7TAB1 | |
| Hydrochloric Acid SCHEMBL1396055 | 0.76 | CPB1 (0.35) | CPB1 | |
| SCHEMBL25195947 | 0.75 | CPB1 (0.43) | ACVR1LRRK2CPB1 | |
| SCHEMBL24925589 | 0.75 | CPB1 (0.40) | CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730119-B1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-06-25 | — | — | EP | claimed |
| US-7342118-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-11 | — | — | US | claimed |
| US-7795447-B2 | 4-(Acylaminoacetylamino)imidazole derivatives, e.g., methyl 3-(4-{2-[2-(3,5-Difluorophenyl)acetylamino]pentanoylamino}imidazol-1-yl)butyrate; treating neurodegenerative and/or neurological disorders such as Alzheimer's disease and Down's Syndrome | PFIZER INC (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-09-18 | — | — | US | disclosed |
| EP-1730119-B1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-7342118-B2 | Imidazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168107-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | BACE1 4/4885KDM2B 2790/4885MET 3450/4885 |
| US-20080227781-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, PSEN2 | BACE1 4/4885KDM2B 2790/4885MET 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.